Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22965787 | 0.84 | LMNA (0.36) | LMNA | |
| SCHEMBL10280944 | 0.82 | LMNA (0.39) | ALDH1A1PIK3CDLMNA | |
| SCHEMBL12039794 | 0.80 | LMNA (0.43) | ALDH1A1PIK3CDLMNA | |
| SCHEMBL10081592 | 0.80 | ALDH1A1 (0.31) | ALDH1A1PIK3CD | |
| SCHEMBL8909834 | 0.79 | MEN1 (0.35) | — | |
| SCHEMBL23806584 | 0.78 | LMNA (0.42) | ALDH1A1LMNA | |
| SCHEMBL23694247 | 0.78 | LMNA (0.42) | ALDH1A1LMNA | |
| SCHEMBL23901743 | 0.78 | HTR2A (0.30) | — | |
| SCHEMBL24877023 | 0.78 | LMNA (0.42) | ALDH1A1LMNA | |
| SCHEMBL21575539 | 0.78 | LMNA (0.42) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238430-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | YUMANITY THERAPEUTICS, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-01-25 | — | — | US | disclosed |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230295118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | ENDOTARGET INC. | 2023-09-21 | — | — | US | disclosed |
| EP-3640248-B1 | AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF | BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) | 2023-08-23 | — | — | EP | disclosed |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | PHARMACYCLICS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| EP-4218722-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20090324544-A1 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | PHARMACYCLICS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-7256199-B1 | Pyrimidone derivatives | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| US-7256199-B1 | Pyrimidone derivatives | MITSUBISHI CHEMICAL CORPORATION (JP) | 2007-08-14 | — | — | US | disclosed |
| US-7247634-B2 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238430-A1 | ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF | CA14, CA12, CA13 | ALDH1A1 228/4885PIK3CD 2330/4885LMNA 3665/4885 |
| US-20230295118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | CDK6, CDK4, CDK1 | ALDH1A1 2308/4885PIK3CD 1509/4885LMNA 1669/4885 |
| US-20090324544-A1 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES | EIF2AK2, NSUN2, RNMT | ALDH1A1 740/4885PIK3CD 593/4885LMNA 3292/4885 |
| US-20240208964-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | ALDH1A1 945/4885PIK3CD 3769/4885LMNA 1215/4885 |
| US-20240065971-A1 | METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, BCL6, BCL6B | ALDH1A1 3706/4885PIK3CD 315/4885LMNA 2894/4885 |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4461/4885PIK3CD 101/4885LMNA 4052/4885 |
| US-20230248730-A1 | USE OF INHIBITORS OF BRUTONS TYROSINE KINASE (BTK) | BTK, LYN, SYK | ALDH1A1 3452/4885PIK3CD 207/4885LMNA 4363/4885 |
| US-20240024488-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ALDH1A1 2571/4885PIK3CD 1146/4885LMNA 225/4885 |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | BTK, LCK, LYN | ALDH1A1 3930/4885PIK3CD 61/4885LMNA 3672/4885 |
| US-20080139582-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcinogenic and antiinflammatory agents | BTK, LCK, LYN | ALDH1A1 3498/4885PIK3CD 76/4885LMNA 3938/4885 |
| US-11802132-B2 | Small molecules for inducing selective protein degradation and uses thereof | BAZ2A, BRD3, BRPF3 | ALDH1A1 4164/4885PIK3CD 4325/4885LMNA 3200/4885 |
| US-20080076921-A1 | 4-Amino-3-phenyl-1H-pyrazolo[3,4-d]pyrimidine derivatives; can be covalently bonded to Bruton's tyrosine kinase; autoimmune diseases, lymphoma, leukemia; antiproliferative, anticarcingogenic and antiinflammatory agents | BTK, LCK, LYN | ALDH1A1 3500/4885PIK3CD 80/4885LMNA 3962/4885 |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | ALDH1A1 3729/4885PIK3CD 946/4885LMNA 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.